DDW IBD 2016 - ARCHIVED SYMPOSIUM

DDW ARCHIVED Symposium

PROGRAM Information

Target Audience

This activity has been designed to meet the educational needs of gastroenterologists and other healthcare providers involved in the care of patients with inflammatory bowel disease (IBD).

Educational Objectives

Upon completing this program, participants should be better able to:

Personalize treatment plans for patients based on risk of aggressive disease

Describe recent advances with current and emerging IBD therapies

Identify proactively patients with iron deficiency anemia

Differentiate among various oral and IV iron formulations and incorporate them effectively into clinical practice


For more information, email us at info@GiHealthFoundation.org, or call 1-877-782-4532.

featuring

(select a speaker to view their bio and disclosure)

Maria T.
Abreu, MD

Miller School of Medicine
University of Miami
Miami, FL

David G.
Binion, MD

University of Pittsburgh
Pittsburgh, PA

Stephen B.
Hanauer, MD

CHAIR
Feinberg School of Medicine
Northwestern University
Chicago, IL

Gary R.
Lichtenstein, MD

Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Edward V.
Loftus Jr., MD

Mayo Clinic
Rochester, MN

Agenda

01:04

Welcome and Introduction

02:27

Clinical Case Discussions

Predicting Risk of Complicated Disease

Current Therapeutic Algorithms

Managing Loss of Response to Biologic Therapies

Managing Iron Deficiency Anemia in IBD

01:00:42

Unmet Needs in IBD: Reviewing the Evidence for
Novel Therapeutics

01:09:16

Panel Discussion and Q&A

01:23:57

Closing Remarks

Maria T. Abreu, MD

Maria T. Abreu, MD, completed her medical degree at the University of Miami, Miller School of
Medicine, where she served as Student Council President and was inducted into the Iron Arrow
Honor Society. Her postdoctoral training included an internship and residency in medicine at
the Brigham and Women's Hospital in Boston, Massachusetts; clinical and research fellowship
in gastroenterology at theUniversity of California, Los Angeles(UCLA), and training in molecular
and cancer biology at UCLA. She was an Associate Professor of Medicine with Mount Sinai School
of Medicine, NYC, prior to returning tothe University of Miami, Miller School of Medicine as Chief
of Gastroenterology and Professor of Medicine.

Dr. Abreu is a Diplomate of the National Board of Medical Examiners, the American Board of
Internal Medicine, and the American Board of Gastroenterology and a Fellow of the American
College of Physicians. She served as Chair of the Underrepresented Minorities Committee of
the American Gastroenterological Association (AGA) and is now Chair of the Immunology,
Microbiology & Inflammatory Bowel Diseases (IMIBD) Section of the AGA Institute Council.
She is a member of the AGA Public Affairs and Advisory Committee, 2014/2015 AGA Institute
Council Chair, the American College of Gastroenterology's Women's Committee, and the Crohn's
and Colitis Foundation of America (CCFA). She was the 2014 President for the Board of the
Florida Chapter of the CCFA and in 2009 was recognized for her education, support and advocacy
for this organization. Dr. Abreu was selected Co-Director of the AGA's 2011 Spring Postgraduate
course and she was also the 2014 President of the Florida Gastroenterology Society. She was
recently appointed to the Advisory Board for The Institute for Children and Adolescents with
Cancer within the University of Miami Sylvester Comprehensive Cancer Center. Dr. Abreu was
elected to the American Society for Clinical Investigation in 2010 and she is listed in
Castle Connolly as one of America's Top Doctors.

Dr. Abreu has authored more than 100 peer-reviewed articles, books, chapters and reviews.
Additionally, she serves as an editorial board member for Inflammatory Bowel Diseases
and Gastroenterology & Hepatology News; editor for the Journal of Immunology;
Associate
Editor of Journal of Crohn's & Colitis and reviewer for several journals. Her research interests
include host-bacterial interactions and the role of toll-like receptor signaling in intestinal
inflammation and colon cancer. Her translational work has focused on genotype-phenotype
relationships in inflammatory bowel disease and prediction of response to medical therapies.
Dr. Abreu is a frequent speaker at national and international symposia on basic science and
clinical topics.

Speaker Disclosure

Grants/Research Support: NIH, CCFA, and CCFA Broad Foundation

Consultant: AbbVie Inc., Asana Medical Inc., Celgene Corporation, Cornerstones Health, ECCO
Congress (European Crohn's & Colitis Organization), Eli Lilly and Company, Ferring
Pharmaceuticals, GlaxoSmithKline Holdings (Americas), Hospira, Inc., Imedex, Inc. Janssen
Biotech, Inc, Mucosal Health Board, Pfizer Inc., Pre-Med Institute, LLS, Prometheus, Prova
Education Inc., Sanofi, Shire, Takeda Pharmaceutical Company Limited, UCB S.A., WebMD Health

David G. Binion, MD

David G. Binion, MD, is a Professor of Medicine and Professor of Clinical and Translational Science
in the Division of Gastroenterology, Hepatology, and Nutrition at the University of Pittsburgh
School of Medicine in Pittsburgh, Pennsylvania, USA. He also serves as Co-Director of the
Inflammatory Bowel Disease Center and Director of Translational Inflammatory Bowel Disease
Research at University of Pittsburgh Medical Center (UPMC), where he is also Director of the
Nutrition Support Service. After graduating from Harvard College in Cambridge, Massachusetts,
he completed his MD at the State University of New York in Buffalo and his internship and
residency at Rhode Island Hospital, Brown University Program in Medicine in Providence, Rhode
Island. After completing a gastroenterology fellowship at the University Hospitals of Cleveland,
Dr. Binion was a Research Associate in mucosal immunology at Case Western Reserve University,
also in Cleveland, where he also completed a postdoctoral fellowship in vascular biology at
the Cleveland Clinic Foundation. Dr. Binion joined the staff at the Medical College of Wisconsin
in Milwaukee, Wisconsin as an Assistant Professor of Medicine in 1997, where he rose to the rank
of Professor of Medicine in 2007. Dr. Binion founded and directed the Inflammatory Bowel Disease
Program at the Medical College of Wisconsin before joining the University of Pittsburgh in 2008.

Dr. Binion's research interests focus on the molecular and cellular mechanisms of human
inflammatory bowel disease and Clostridium difficile infection. His recent investigation has
focused on the heterogeneity of IBD patient subgroups and characterization of clinical
trajectories with the goal of implementing precision treatment and personalized medicine.
He has published over 150 refereed articles, reviews and book chapters, and has authored over
250 scientific abstracts presented at national and international congresses.

Dr. Binion has received the Premier Physician Award from the Crohn's and Colitis Foundation
of America, and is a Fellow of the American College of Gastroenterology and the American
Gastroenterological Association.

Speaker Disclosure

Grants/Research Support: Janssen Biotech, Inc., Merck, UCB, S. A.

Stephen B. Hanauer, MD

Stephen B. Hanauer, MD, is currently president of the American College of Gastroenterology.
He completed a medical degree, with honors, at the University of Illinois in Chicago. His
postdoctoral training included an internship and residency in internal medicine as well as a
fellowship in gastroenterology at the University of Chicago. He rose through academic ranks
to become professor of medicine and subsequently was awarded the Joseph B. Kirsner Chair in
Medicine and designated chief of the Section of Gastroenterology, Hepatology, and Nutrition,
where he served from 2000 to 2014. He was recruited as the medical director of the Digestive
Health Center at Northwestern Medicine and is the Clifford Joseph Barborka Professor of Medicine
in the Northwestern Feinberg School of Medicine as of January 1, 2014.

Dr. Hanauer is board certified in internal medicine and gastroenterology by the American Board
of Internal Medicine and the American Board of Gastroenterology, respectively. He holds
membership in several professional societies and is a Fellow of the American Gastroenterological
Association (AGA), the American College of Gastroenterology, and the American College of
Physicians. In connection with the AGA, Dr. Hanauer served as chair for the Inflammation,
Immunology, and Inflammatory Bowel Disease Section and the Clinical Practice Section and
subsequently served as councilor for clinical research on the AGA Governing Board. He is a
prior member of the Specialty Board of the American Board of Internal Medicine. Among his
many honors, Dr. Hanauer received the AGA Fiterman Foundation Joseph B. Kirsner Award in
Gastroenterology in 2001 and the Janssen Award for Clinical Excellence in 2004. He has served
as a member and chair of the US Food and Drug Administration Advisory Panel for Gastrointestinal
Disorders and is a member and former-chairman of the International Organization for
Inflammatory Bowel Disease.

Dr. Hanauer has authored hundreds of peer-reviewed journal articles, books and book chapters,
abstracts, monographs, and editorials. He is ex-editor-in-chief of Nature Clinical Practice
Gastroenterology & Hepatology and currently serves as associate editor (IBD) of Clinical
Gastroenterology and Hepatology. He is also a member of the editorial boards of numerous
journals, including the American Journal of Gastroenterology, and Inflammatory
Bowel Diseases.

Speaker Disclosure

Grant/Research Support: AbbVie Inc., Amgen Inc., Celgene Corporation, Janssen Biotech, Inc.,
Luitpold Pharmaceuticals, Inc./ American Regent, Inc., Pfizer Inc., Prometheus, Receptos, Inc.,
Takeda Pharmaceuticals Company Limited, Inc., UCB, Inc.

Consultant/Speaker Bureau: AbbVie Inc., Actavis, Amgen Inc., Celgene Corporation, Celltrion
Inc., Ferring Pharmaceuticals, Hospira, Inc., Janssen Biotech, Inc., Luitpold Pharmaceuticals,
Inc./American Regent, Inc., Nestle Health Science, Pfizer Inc., Prometheus, Receptos, Inc., Salix
Pharmaceuticals, Inc., Seres Health, Inc., Shire, Takeda Pharmaceuticals Company Limited, Inc.,
UCB, S.A.

Gary R. Lichtenstein, MD

Gary R. Lichtenstein, MD, FACP, FACG, AGAF, is the director of the Inflammatory Bowel Disease
Center and a professor of medicine in the Gastrointestinal Division of the Department of Medicine
at the Hospital of the University of Pennsylvania and the University of Pennsylvania School of
Medicine in Philadelphia, Pennsylvania.

Dr. Lichtenstein earned his medical degree from the Mount Sinai School of Medicine, in New York,
New York. He then completed his internship and residency in internal medicine at Duke University
Medical Center, in Durham, North Carolina. He also served a fellowship in gastroenterology at
the Hospital of the University of Pennsylvania of the University of Pennsylvania School of Medicine.
His current research interests encompass investigational therapies for the treatment of ulcerative
colitis and Crohn's disease, and he has received numerous research grants focusing on these areas.
Dr. Lichtenstein has served as the national/ international principal investigator evaluating novel
agents for therapeutic trials in the treatment of ulcerative colitis and Crohn's disease.

A Fellow of the American Gastroenterological Association (AGA), the American College of
Physicians, and the American College of Gastroenterology (ACG), Dr. Lichtenstein has been
listed in “Best Doctors in America” (inflammatory bowel disease), and he has served as medical
secretary for the American Board of Internal Medicine, Gastroenterology Section. He holds
membership and committee positions in many professional societies at a national level,
including the AGA, where he has served as vice-chair of the clinical practice committee
and practice economics committee and as chair of the clinical practice committee;
the American Society for Gastrointestinal Endoscopy, where he has served on the committee
on training; and the ACG, where he has served on the education committee, programs committee,
and the nominations committee as well as recently serving as a member of the research committee.
He has also been the chair of the abstract review committee for inflammatory bowel disease for
the ACG. He is a member of the Crohn's and Colitis Foundation of America (CCFA) where he served
at the national level as the chair of the membership committee of the Clinical Research Alliance,
on the national grants review committee, and on the national physician education committee.
In addition, he is a longstanding member of the American College of Physicians and the American
Medical Association.

Dr. Lichtenstein has received numerous awards, including the award for the top specialist in the
University of Pennsylvania Health System, the Louis A. Duhring Award. He is the recipient of the
Christina and Marie Lindback Award, the top teaching award at the University of Pennsylvania and
the medical school teaching award, the Penn Pearls Award. He has received the Department of
Medicine Housestaff teaching award, the Donald B. Martin Teaching Award and the
Gastroenterology Division teaching award, the Sidney Cohen Teaching Award. He is listed in “The
Best Doctors in America” (inflammatory bowel disease) and in Philadelphia Magazine as being
among the top gastroenterologists for the elderly in Philadelphia and also among the top
gastroenterologists in Philadelphia (Special Focus: Inflammatory Bowel Disease). He is also the
recipient of the CCFA Physician of the Year Award: Philadelphia and Delaware Valley Chapters.

In addition to having served on the editorial board of the journals Gastroenterology, the American
Journal of Gastroenterology, Inflammatory Bowel Diseases, the World Journal of
Gastroenterology, and Digestive Diseases and Sciences, Dr. Lichtenstein has served as a
former writer of selected summaries in the journal Gastroenterology, as the section editor of
selected summaries and the section editor of print and media review in gastroenterology for a
5-year term. He also has served and currently serves as a reviewer for such journals as the
New England Journal of Medicine, Gastroenterology, The Lancet, the Annals of Internal Medicine,
Gut, the Journal of Parenteral and Enteral Nutrition, the American Journal of Gastroenterology,
the World Journal of Gastroenterology, and the Journal of Clinical Gastroenterology. He is executive
editor of a newly PubMed-indexed journal Gastroenterology & Hepatology, and serves as associate
editor of Therapeutic Advances in Gastroenterology, The Physician and Sportsmedicine, and the
Journal of Clinical Investigation. He is currently assistant editor-in-chief of the World Journal of
Gastroenterology. An invited lecturer at local, national, and international levels, Dr. Lichtenstein
is the author or coauthor of more than 250 peer-reviewed primary articles, chapters, letters, and
editorials. He has presented over 250 abstracts and edited 18 books. He has lectured at a national
and international level at more than 300 invited conferences, symposia, and institutional grand
rounds.

Speaker Disclosure

Author: McMahon Publishing, UpToDate

Book Royalty: SLACK, Inc.

Editorial Board Involvement: Clinical Advances in Gastroenterology, Gastroenterology &
Hepatology
(Gastro-Hep Communications), Springer Science+Business Media

Funding to University of PA (IBD Fellow Education): Janssen Orthobiotech

Grant /Research Support: Ferring B.V., Janssen Orthobiotech, Prometheus Laboratories, Inc.,
Salix, a division of Valeant Pharmaceuticals North America LLC, Santarus Inc., Shire
Pharmaceuticals, UCB S.A., Warner Chilcott Pharmaceuticals

Consultant/Speaker Bureau: Abbott Corporation, AbbVie Inc., Activis, Alaven, Ferring B.V.,
Hospira, Inc., Janssen Orthobiotech, Luitpold Pharmaceuticals, Inc./American Regent, Inc., Pfizer
Inc., Prometheus Laboratories, Inc., Romark, Salix, a division of Valeant Pharmaceuticals North
America LLC, Santarus Inc., Shire, Takeda Pharmaceutical Company Limited, UCB S.A., Warner
Chilcott Pharmaceuticals

Honorarium Recipient: Clinical Advances in Gastroenterology, Gastroenterology and
Hepatology
(Gastro-Hep Communications), Ironwood, Luitpold Pharmaceuticals, Inc./American
Regent, Inc., McMahon Publishing, Springer Science+Business Media, UpToDate

Speaker: AbbVie Inc., Janssen Products, LP, Takeda Pharmaceutical Company Limited

EDWARD V. LOFTUS JR., MD

Edward V. Loftus Jr., earned a medical degree at the University of Pennsylvania and completed
a residency in internal medicine at Temple University Health Sciences Center in Philadelphia.
He served one year as a general medical officer in the Indian Health Service at Fort Belknap P.H.S.
Indian Hospital in Harlem, Montana, and then completed a fellowship in gastroenterology at the
Mayo Graduate School of Medicine. He has been on the Mayo Clinic consulting staff since 1995.

Dr. Loftus is a Fellow of the American College of Physicians (ACP), the American College of
Gastroenterology (ACG), and the American Gastroenterological Association (AGA). He is a member
of several professional societies, including the ACP, AGA, ACG, American Society for
Gastrointestinal Endoscopy, and the Crohn's & Colitis Foundation of America (CCFA). He served
as Chair of the Patient Education Committee of the CCFA from 2002 to 2005. He has served on
several ACG committees, and has been an abstract reviewer for both AGA and ACG for a number
of years. He is currently the Chair of the Immunology, Microbiology, and Inflammatory Bowel
Disease section of the AGA Institute Council.

Among Dr. Loftus's awards are the Mayo Department of Medicine Laureate Award (2007) and the
CCFA, Minnesota - Dakotas Chapter, Physician of the Year Award (2008). He was elected to
membership in the International Organization for the Study of Inflammatory Bowel Disease
(IOIBD) in 2008. Dr Loftus was named Teacher of the Year by the Mayo gastroenterology fellows
in 2010-11. He has been named to the list of Best Doctors in America since 2005 and to Castle
Connolly's Top Doctors in America list since 2010.

He served as Associate Editor of the American Journal of Gastroenterology between 2003 and
2009, and as Associate Editor of Inflammatory Bowel Diseases from 2006 to 2013.

Dr. Loftus has published over 270 original articles, book chapters, or editorials and more than
300 abstracts, and has lectured extensively on the epidemiology, natural history, diagnosis,
and medical management of inflammatory bowel diseases. Dr. Loftus has served as the principal
investigator on several funded studies focusing on the epidemiology and natural history of
inflammatory bowel disease.

Speaker Disclosure

Grant/Research Support: AbbVie Inc., Amgen Inc., Celgene Corporation, Genentech, Gilead
Sciences, Inc., Janssen Biotech, Inc., Pfizer Inc., Receptos, Robarts Clinical Trials, Takeda
Pharmaceutical Company Limited, UCB S.A.

Consultant/Speaker Bureau: AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company,
Janssen Biotech, Inc., Mesoblast, Seres Health, Sun Pharmaceutical Industries Ltd., Takeda
Pharmaceuticals Company Limited, Inc., UCB S.A.

© Copyright 2013-2017 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.